Last reviewed · How we verify
Bezuclastinib in combination with sunitinib
Bezuclastinib is a tyrosine kinase inhibitor that targets KIT and PDGFRα, and in combination with sunitinib, it is used to treat gastrointestinal stromal tumors (GIST).
Bezuclastinib is a tyrosine kinase inhibitor that targets KIT and PDGFRα, and in combination with sunitinib, it is used to treat gastrointestinal stromal tumors (GIST). Used for Gastrointestinal stromal tumors (GIST).
At a glance
| Generic name | Bezuclastinib in combination with sunitinib |
|---|---|
| Sponsor | Sarcoma Alliance for Research through Collaboration |
| Drug class | tyrosine kinase inhibitor |
| Target | KIT, PDGFRα |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Bezuclastinib works by inhibiting the activity of KIT and PDGFRα, which are proteins that help cancer cells grow and divide. By blocking these proteins, bezuclastinib can slow or stop the growth of cancer cells. When used in combination with sunitinib, bezuclastinib may help to improve treatment outcomes for patients with GIST.
Approved indications
- Gastrointestinal stromal tumors (GIST)
Common side effects
- Fatigue
- Hypertension
- Diarrhea
- Nausea
- Vomiting
Key clinical trials
- First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (PHASE1)
- SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: